ArticleTherapeutic advances in gastroenterology2026
Risk factors for appendicitis recurrence after ERAT in patients with acute appendicitis: a multicenter cohort study with long-term follow-up.
Article in Therapeutic advances in gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endoscopic retrograde appendicitis therapy (ERAT) has emerged as a minimally invasive approach to treating appendicitis. Objectives: This study aimed to assess the long-term safety and efficacy of ERAT and to develop a model predicting 1‑year appendicitis recurrence in patients with acute appendicitis, to guide clinical decision-making. Design: This is a multicenter retrospective study. Consecutive patients were referred to the three participating centers. Methods: A retrospective analysis was conducted on clinical data from 435 patients with acute appendicitis who underwent ERAT at three hospitals between October 2017 and October 2024. Twenty-four clinical variables were screened, and Spearman correlation analysis revealed correlation coefficients exceeding 0.6 between some variables. To address multicollinearity, LASSO regression was employed to identify key predictive factors in the training set. A predictive model was constructed using multivariate logistic regression, and a nomogram was developed. Results: All ERAT procedures were technically successful, and a clinical success rate of 92.4% was achieved. The median follow-up period was 37 months, and the overall recurrence rate was 16.1%; most recurrences (13%) were observed in the first year. Based on LASSO regression analysis, the final predictors identified were: age >60 years (odds ratio (OR) = 2.981, 95% confidence interval (CI): 1.368-6.497, Conclusion: ERAT is a safe and effective treatment for acute appendicitis. The risk of recurrence is highest within the first year. Eight independent risk factors for recurrence within 1 year after ERAT were identified, and a recurrence risk prediction model based on these predictive factors can assist in future clinical decision-making for ERAT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.